2-47806344-C-T
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 0P and 3B. BP4_ModerateBP6
The NM_000179.3(MSH6):c.3787C>T(p.Arg1263Cys) variant causes a missense change. The variant allele was found at a frequency of 0.0000235 in 1,613,930 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000179.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152108Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000159 AC: 4AN: 251218Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135778
GnomAD4 exome AF: 0.0000233 AC: 34AN: 1461822Hom.: 0 Cov.: 33 AF XY: 0.0000248 AC XY: 18AN XY: 727206
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152108Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74296
ClinVar
Submissions by phenotype
Lynch syndrome 5 Uncertain:2Benign:1
- -
- -
This variant is classified as a variant of uncertain significance as there is insufficient evidence to determine its impact on protein function and/or cancer risk. -
not provided Uncertain:2
The frequency of this variant in the general population, 0.000031 (4/128982 chromosomes, http://gnomad.broadinstitute.org), is uninformative in assessment of its pathogenicity. In the published literature, the variant has been reported in individuals with breast cancer (PMID: 35449176 (2022), 32658311 (2021)) and colorectal cancer (PMID: 28135145 (2017)). In a large-scale breast cancer association study, the variant was observed in individuals with breast cancer as well as in unaffected individuals (PMID: 33471991 (2021), see also LOVD (http://databases.lovd.nl/shared/genes/MSH6)). Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded conflicting predictions that this variant is benign or damaging. Based on the available information, we are unable to determine the clinical significance of this variant. -
Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Observed in individuals with colorectal cancer, breast cancer, or Ewing's sarcoma (Yurgelun et al., 2017; Akcay et al., 2020; Papi et al., 2022); This variant is associated with the following publications: (PMID: 25583476, 23621914, 31391288, 28135145, 17531815, 21120944, 32658311, 35903703) -
Hereditary cancer-predisposing syndrome Uncertain:2
This missense variant replaces arginine with cysteine at codon 1263 of the MSH6 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in an individual affected with colorectal cancer (PMID: 28135145). This variant has been identified in 5/282616 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
The p.R1263C variant (also known as c.3787C>T), located in coding exon 8 of the MSH6 gene, results from a C to T substitution at nucleotide position 3787. The arginine at codon 1263 is replaced by cysteine, an amino acid with highly dissimilar properties. This variant has been reported in an individual diagnosed with colorectal cancer (Yurgelun MB et al. J Clin Oncol, 2017 Apr;35:1086-1095). This alteration was also seen in 1/732 breast cancer patients, 0/189 colorectal cancer patients and 1/490 cancer-free elderly controls in a Turkish population (Akcay IM et al. Int J Cancer, 2021 01;148:285-295). This alteration was also identified in an individual diagnosed with prostate cancer (Gheybi K et al. J Natl Compr Canc Netw, 2023 Mar;21:289-296.e3). This variant has been identified in probands whose Lynch syndrome-associated tumors were microsatellite stable (MSS) and/or demonstrated normal mismatch repair protein expression by immunohistochemistry (IHC) (Ambry internal data). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
not specified Uncertain:1
Variant summary: MSH6 c.3787C>T (p.Arg1263Cys) results in a non-conservative amino acid change located in the DNA mismatch repair protein MutS, C-terminal (IPR000432) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function, and the PON-MMR2 tool predicts a benign effect (Niroula_2015). The variant allele was found at a frequency of 1.6e-05 in 251218 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.3787C>T has been reported in the literature in individuals affected with cancer (including colorectal cancer) without strong evidence of causality (Hu_2022, Akcay_2021, Yurgelun_2017, Li_2020, Muskens_2020). These reports do not provide unequivocal conclusions about association of the variant with Lynch Syndrome. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 35449176, 26333163, 32658311, 28135145, 31391288, 31970404). Seven submitters have provided clinical-significance assessments for this variant to ClinVar after 2014 , and classified it as uncertain siginificance (n=5), or likely benign (n=2). Based on the evidence outlined above, the variant was classified as uncertain significance. -
Lynch syndrome Uncertain:1
This missense variant replaces arginine with cysteine at codon 1263 of the MSH6 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with colorectal cancer (PMID: 28135145), in an individual affected with an unspecified cancer (PMID: 31391288), as well as in both cases and controls in breast cancer studies (PMID: 32658311, 33471991, 35449176). This variant has been identified in 5/282616 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Endometrial carcinoma Uncertain:1
- -
Hereditary nonpolyposis colorectal neoplasms Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at